![ResMed Overview ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],NYSE / ASX: RMD 1 Frost & Sullivan 2004 reported $1B but growth is ~20%](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Empfohlen
Empfohlen
Weitere ähnliche Inhalte
Was ist angesagt?
Was ist angesagt? (20)
Ähnlich wie Res med bby_healthcare
Ähnlich wie Res med bby_healthcare (20)
Mehr von Golden Gate University
Mehr von Golden Gate University (11)
Res med bby_healthcare
- 1. ResMed Inc Klaus Schindhelm Senior Vice President, Applied Research Global
- 3. Strong Financial Performance Annual US$ (Million) *Excluding stock-based compensation, restructuring, and acquisition-related costs
- 4. Sales by Product Category Q1 of FY’07 Masks, Accessories 50% CPAP/APAP 31% VPAP/Saime 19%
- 5. Sales by Geographic Region Q1 of FY’07 Americas 55% Europe 38% Asia-Pacific 7%
- 8. US Market Opportunity SDB Prevalence Diagnosed Treated New User Share Compliant Share Adult population 221.3M 44M 4M 4M 2.5M 44M
- 9. Growth Drivers SDB Prevalence Diagnosed Treated New User Share Compliant Share Public Relations Physician Education Healthysleep.com ApneaLink Comorbidity Initiatives New Products Business Solutions Branding myresmed.com
- 12. Growth in SDB Publications
- 13. Sleep Apnea Prevalence in Cardiovascular Disease Patients Logan et al. J. Hypertension 2001 Javaheri et al. Circulation 1999 Sjostrom et al. Thorax 2002 Schafer et al. Cardiology 1999 Sanner et al. Clin Cardiology 2001 Somers et al. Circulation 2004 80%+ 70% 50-70% 35-45% ~30% ~30% Erman et al. APSS 2005 ~50%
- 17. High $ New Product Cycle Med $ Low $ Basic Full Unique © ResMed 2006 FEATURES PRICE Specialty Segment VPAP Adapt SV Premium Segment S8 Platform, VPAP Bilevel Value Segment C Series Tango